Armenia vs Namibia: Average cost of multi drug-resistant tuberculosis treatment
Armenia
2,970 constant 2022 US$
in 2024
Namibia
3,336 constant 2022 US$
in 2024
Armenia rank
16th
Namibia rank
14th
Average cost of multi drug-resistant tuberculosis treatment over time
- Armenia
- Namibia
How they compare
Namibia currently reports 3,336 constant 2022 US$ against 2,970 constant 2022 US$ in Armenia, a difference of 366 constant 2022 US$.
That makes Namibia's figure about 1.1 times Armenia's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Armenia ahead.
Armenia ranks 16th and Namibia ranks 14th of 92 countries.
Armenia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Armenia | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,850 constant 2022 US$ | 3,580 constant 2022 US$ | 1,270 constant 2022 US$ | Armenia |
| 2020s | 4,196 constant 2022 US$ | 2,966 constant 2022 US$ | 1,230 constant 2022 US$ | Armenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Armenia or Namibia?
- Namibia, at 3,336 constant 2022 US$ against 2,970 constant 2022 US$ in Armenia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Armenia and Namibia?
- 366 constant 2022 US$, with Namibia ahead.
- How many years of comparable data are there for Armenia and Namibia?
- 6 years are reported by both, from 2019 to 2024.
- How do Armenia and Namibia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Armenia ranks 16th and Namibia ranks 14th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.